Since I initiated coverage of Neogenomics (NASDAQ:NEO) in mid-October, 2011, share price of the company almost tripled as of this writing. Here comes the logical question: what's next for Neogenomics?
We are still optimistic about the prospect of Neogenomics, and think there are still a plenty of room for price appreciation in the next 12 months.
Our call is based on the company's strong financials, business development and management credibility.
(click to enlarge)(click to enlarge)(click to enlarge)
Second Quarter Revenue In Line With Our Expectation
On July 31, Neogenomics reported financial results for the second quarter ending June 30, 2013.
Revenue for the second quarter was $15.6 million, unchanged from second quarter 2012 revenue. 2Q13 revenue
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|